Qiagen, Inovio to partner on cervical dysplasia test

By LabPulse.com staff writers

February 24, 2021 -- Qiagen and Inovio have announced they will develop a next-generation sequencing (NGS) test for HPV-linked advanced cervical dysplasia that can be used on Illumina's NextSeq 550Dx platform.

The liquid biopsy-based test aims to guide patient selection and offer a noninvasive alternative to having cervical lesions removed. It will be a companion test for Inovio's VGX-3100. Qiagen's expertise in bioinformatics will boost the predictive power of Inovio's preliminary biomarker signature.

Qiagen plans FDA resubmission of coronavirus rapid antigen test
Qiagen is planning a first-quarter resubmission of its QIAreach rapid antigen test to the U.S. Food and Drug Administration (FDA). In separate news, the...
Qiagen debuts solution for SARS-CoV-2 T-cell research
Qiagen has launched the QuantiFeron SARS-CoV-2 Research Use Only solution to detect T-cell responses to the novel coronavirus. The solution could aid...
Qiagen releases portable SARS-CoV-2 antigen test
Qiagen has launched a portable, digital SARS-CoV-2 antigen test that can analyze more than 30 swab samples per hour. The company developed the QIAreach...
Laboratories, IVD vendors get to work on novel coronavirus
The emergence of novel viruses underscores the need for laboratories to be vigilant and for IVD vendors to constantly update test menus, writes Bruce...
Qiagen liquid biopsy to guide Inovio immunotherapy
Qiagen is developing a liquid biopsy companion diagnostic for Inovio's investigational VGX-3100 immunotherapy for the nonsurgical treatment of advanced...

Copyright © 2021 LabPulse.com

Last Updated ls 2/24/2021 3:57:45 PM